logo
Skywatch: Crowded space

Skywatch: Crowded space

Yahoo11-05-2025

A little over 240 years ago, birds were the only things that could fly above the ground untethered without eventually falling. That all changed in 1783 when Jean-François Pilâtre de Rozier and François Laurent d'Arlandes made the first successful hot-air balloon flight over Paris. Just think about what must have been going through their heads when they saw the Earth from above. No humans had ever had a bird's-eye view like that before and lived to tell about it!
It took until 1903 for the next major aviation feat to be accomplished when the Wright brothers flew the first airplane in the skies just south of Kitty Hawk, N.C. Fifty-four years later, the Soviet Union put the first human-made satellite, Sputnik 1, in orbit around the Earth, and four years after that, the Russians launched the first human-occupied satellite, Vostok 1, with astronaut Yuri Gagarin aboard.
Since that time over 11,000 satellites have been launched into orbit, with and without people aboard. Many of those satellites have long since burned up in the Earth's atmosphere because of orbital decay. Others, mainly occupied by humans, have successfully re-entered the atmosphere to either land on the ground or splash down in the ocean. There is a fantastic website, www.N2YO.com, that tracks objects in the sky. If you go to their search engine and type in Vanguard 1, you can see that it is in the first position of one of the first U.S. satellites launched in 1958 and is still in orbit 67 years later! When you explore N2YO, you can get orbital data on thousands in orbit. However, many of those satellites have stopped functioning, and many are actually spent rocket stages that boosted satellites into orbit. It's crowded above the Earth, but there's still a lot of room left.
The really cool thing is that stargazers can see many of these satellites. If you're intently studying the night sky looking for constellations and observing with binoculars or a telescope, it's hard to go more than a half-hour without seeing a satellite zipping along. Most satellites move from west to east, but some are in polar orbits. The best time to see them is in the early evening for a couple of hours after evening twilight or a couple of hours before the start of morning twilight. That's because satellites have to reflect sunlight to be visible. Even if satellites had huge spotlights mounted on them, you'd never see them. They're just too high up. Just before morning twilight, and for a little while after evening twilight, there's no direct sunlight available to us on the ground, but high in space there's still enough sunlight to bathe satellites, sending secondhand sunshine our way. During the middle of the night the sun is entirely behind the Earth, so all satellites pass over in total darkness.
By far, the easiest satellite to spot is the International Space Station. It's as bright as a jetliner passing over. Because of that many people see it all the time and figure it's a jet. Its first component or module was launched in 1998, and the station was completed in 2011. It's longer than a football field! What makes it so bright are the eight solar panels that are over 100 feet long and nearly 40 feet wide! They bounce a heck of a lot of secondhand sunshine our way!
The ISS orbits the Earth about every 90 minutes, traveling at almost 5 miles a second. It moves in a general direction from west to east across the dome of the sky. The ISS doesn't pass over the same location each orbit. That's because of the nature of its orbit and the fact that Earth is rotating. There can be stretches of nights when it doesn't pass over at all. That's why you need to have an app or a website that will let you know where and when to look. Some apps will even alert you when the ISS is expected to pass over your location on Earth.
My favorite website for keeping up with the travels of the ISS is www.heavensabove.com. With Heavens-Above all you have to do is configure it for your location with their massive database. Among many of its features, it'll provide a schedule for ISS flyovers and even a sky map to track it. You can also find out when other bright satellites will be passing over. My favorite free app for tracking the ISS is ISS Tracker. Allow that app to know your location, and you're good to go.
Depending on where it's crossing your sky, the ISS can take up to around five minutes to pass. It resembles a super bright star. Depending on when you're watching it, in the early morning or early evening, it can suddenly disappear in the sky as it enters the Earth's shadow, or it can pop into view coming out of the shadow in the early morning.
As much fun as it can be to observe satellites in the night sky, I'm afraid that in the future the skies may become too crowded. I'm worried that it's already beginning to happen. In particular I'm referring to Starlink satellites launched by the Space Exploration Technologies Corporation, otherwise known as SpaceX, a private space transportation enterprise founded in 2002 by South African native Elon Musk.
Starlink satellites can provide much more available access to the internet throughout the world, even in remote areas. Already, there are hundreds and hundreds of Starlinks in orbit, and it's very easy to see them, sometimes in groups or lines, especially after they are first launched. As it is with the International Space Station, you can keep up with all of them on the Heavens-Above website, as well as other sites and apps.
The big fear is that the natural beauty of the night sky could be ruined with too many satellites. Earth-based astronomical observations, both done by professionals and by amateur astronomers, are going to be interfered with significantly. I believe, and so do many others, that there must be some international regulations to keep this from happening. I can tell you as an astrophotographer that it's getting tougher and tougher to get time-exposure images that aren't marred by satellite streaks.
Watching satellites is a lot of fun but let's not get the heavens too congested!
Mike Lynch is an amateur astronomer and retired broadcast meteorologist for WCCO Radio in Minneapolis/St. Paul. He is the author of 'Stars: a Month by Month Tour of the Constellations,' published by Adventure Publications and available at bookstores and adventurepublications.net. Mike is available for private star parties. You can contact him at mikewlynch@comcast.net.
Skywatch: Dippers and bears flying high
Skywatch: A crow, a cup and a water snake
Skywatch: The two brightest stars, and a guest star
Skywatch: Celestial twins proudly sharing Orion's shoulders
Skywatch: Out with the hunter. In with the Lion.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation
Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation

Washington Post

time2 hours ago

  • Washington Post

Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation

NEW YORK — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week . They include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a leading critic of pandemic-era lockdowns, and a professor of operations management.

Enough hype about AI in health—let's talk about results
Enough hype about AI in health—let's talk about results

Fast Company

time2 hours ago

  • Fast Company

Enough hype about AI in health—let's talk about results

There's no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative to fund AI infrastructure, while the UK government announced £82.6 million in research funding for three projects, two of which are using AI to tackle cancer and Alzheimer's disease. But ask any patient waiting for a diagnosis, or a clinician searching for certainty, and the real question cuts through all the noise: When will all the innovation deliver real impact where it matters most? We've entered an era where healthcare data is measured in exabytes—genomes, images, clinical notes, labs, and signals from every continent. At SOPHiA GENETICS, we've just achieved the milestone of analyzing 2 million patient profiles. It's a number that was unimaginable a decade ago. Yet the value of data isn't in volume. It's what you do with it. Insight matters only if it changes an outcome, shortens a diagnostic odyssey, or opens up a new chance for a patient. It's time to move from conversation to action. Too often, insights get trapped in institutional silos or left in endless pilot projects, just out of reach of the people who need them. 3 ways AI is already transforming medicine Today, technology can connect, for example, a patient in São Paulo with expertise in Seoul, uncovering patterns invisible to the human eye. Here are several ways AI is helping now. 1. Improving diagnostic accuracy: AI algorithms, particularly those based on deep learning, have demonstrated remarkable accuracy in diagnosing diseases from medical images and test results. These systems are trained on vast datasets, allowing them to recognize patterns and anomalies that might be missed by the human eye. For example, in dermatology, AI systems trained on images of skin lesions have shown the ability to detect skin cancers, such as melanoma, with high levels of precision. 2. Enhancing cancer prevention: AI techniques can be used to screen individuals for genomic markers and develop personalized cancer risk prediction scores. This proactive approach can help screen younger patients for genomic predispositions, empowering them to make informed prevention decisions and proactively monitor their health. 3. Tailoring treatments to genomic profiles: One of the most significant applications of AI is in the field of genomics. AI can analyze vast genomic datasets to identify mutations and variations that might influence an individual's response to certain treatments. For example, our SOPHiA DDM product can identify specific genomic markers that are susceptible to targeted cancer therapies, increasing the efficacy of the treatment and minimizing the risk of adverse reactions, for a more effective and safer treatment plan for patients. To scale up these AI applications there are many regulatory and compliance barriers to overcome. This requires investment in data security, creating clear guidelines, data security measures, and ensuring clinicians are fully trained. Our goal should be to create a regulatory environment that fosters innovation while safeguarding patient data and promoting public trust. We must democratize this powerful data to enable more physicians, practices, and hospitals to incorporate AI into daily clinical use so that a greater number of patients can access data-driven medicine, not just a select few. My message for governments investing in AI is clear: Balance investing in future AI tools with validating existing solutions that have already been proven to improve patient outcomes. Build the bridges that turn breakthroughs into benefits, so that data-driven medicine becomes a reality for every patient.

Fast Five Quiz: Diffuse Large B-Cell Lymphoma
Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Medscape

time2 hours ago

  • Medscape

Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Although diffuse large B-cell lymphoma (DLBCL) is characterized by aggressive clinical behavior, standard treatment can provide good long-term survival outcomes. However, management can be complex, with certain comorbidities exacerbating disease severity and complications such as extranodal involvement significantly affecting prognosis. Understanding the nuances of DLCBL presentation, diagnosis, and management is key to delivering the best outcomes to patients affected by this rapidly progressive disease. What do you know about DLBCL? Check your knowledge with this quick quiz. Both primary and secondary Sjögren syndrome are strongly associated DLBCL. Other autoimmune disorders that have been associated with DLBCL include hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease. In addition to autoimmune disorders, viral infections have also been linked to DLBCL; these include HIV, hepatitis B, hepatitis C, and Epstein-Barr. Further, data have shown that patients with rheumatic diseases have a heightened risk of DLBCL development. Though fugal or bacterial pneumonia, humoral deficiency, and bone infections (such as osteomyelitis) can occur in patients with DLBCL, data have indicated that survivors of DLBCL were more likely to experience these conditions, rather than being strongly linked to DLBCL itself. Learn more about DLBCL staging. In the NCCN's guidelines, PET/CT is the preferred modality for imaging in DLBCL workup. C/A/P CT with contrast can also be used in a complementary setting to help stage the disease and identify other factors such as extranodal disease or visceral involvement, but it is not preferred. Although not essential, head CT/MRI or neck CT/MRI with contrast (as well as bone marrow biopsy) can be useful for workup in selected cases. Specifically, bone marrow biopsy can be helpful in identifying indolent or low-volume disease. However, the NCCN notes that bone marrow biopsy is not needed if PET/CT shows bone disease. Learn more about DLBCL workup. Data indicate that extranodal involvement occurs in approximately 30%– 50% of patients with DLBCL; further, it is reported that gastrointestinal involvement is the most common extranodal site. Other affected sites include the skin, bones, spleen, and central nervous system; kidneys, testicles, and the liver can also be impacted, but they are not regarded as the most common. Learn more about DLCBL and extranodal involvement. A population-based study involving over 30,000 patients with extranodal DLBCL found that the best outcomes are associated with heart and mediastinal sites, with a 42% reduction in mortality risk compared with involvement of the intestinal tract. Involvement of the pancreas and hepatobiliary system, respiratory system, or nervous system are associated with significantly greater risks of mortality compared with the intestinal tract. Other factors associated with greater mortality risk include late age at onset, history of other malignancy, late age at presentation, and Black, non-Hispanic ethnicity. Learn more about DLBCL prognosis. CAR T therapy is typically utilized as a second-line treatment for patients with relapsed/refractory DLBCL. CD19-directed CAR T-cell therapy is considered ' the standard of care' for relapsed/refractory DLBCL, with three treatments approved for this population. Although a number of factors can lead to CAR T cell therapy resistance, the key mechanism is typically down regulation or loss of CD19 expression. Abnormal differentiation and dysfunction of T cells can also cause poor response to CAR T therapy, and being unable to collect enough T cells can also negatively affect the impact of CAR T products; however, these factors are not considered key mechanisms for resistance to CAR T-cell therapy. As such, early collection of T-cells in high-risk patients with DLBCL is one strategy to ensure enough T cells are available when needed. Partial response or relapse after CAR T therapy should prompt third-line therapy, such as alternative systemic therapy not previously given, clinical trial, palliative involved-site radiation therapy, or best supportive care. Learn more about relapsed or refractory DLBCL.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store